Amanda Balbi - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Amanda Balbi's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Amanda Balbi
Verified
Managing Editor, Consultant360
New Jersey
Beats
Criminal
Content
By Amanda Balbi| Population Health Learning Network@ News Roctavian, an adeno-associated virus vector-based gene therapy, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. This approval comes after a safety and effectiveness trial showed that Roctavian improved participants’ annualized bleeding rate after 3 years
By Amanda Balbi| HMP Global Learning Network@ Clinical Insights The National Eczema Association estimates that 31.6 million individuals in the United States have some form of eczema.1 Patients report that itch, skin redness, and dryness are the most burdensome symptoms of disease, and 15% to 30% of patients with atopic dermatitis (AD) report sleep-related issues.1 With patients’ high level of disease burden comes an urgent need for novel treatment options
Company Info
Consultant360
New Jersey, United States